Sana lays off staff as cell ther­a­py biotech awaits first clin­i­cal da­ta

Cell ther­a­py mak­er Sana Biotech­nol­o­gy is lay­ing off staff, based on about half a dozen em­ploy­ee posts on LinkedIn in re­cent days.

Sana ex­pects its first clin­i­cal da­ta lat­er this year — a key test of whether its so-called hy­poim­mune tech­nol­o­gy works at pre­vent­ing the re­jec­tion of al­lo­gene­ic cells, or those not orig­i­nat­ing from the pa­tient. Au­tol­o­gous, or self-de­rived, cell ther­a­pies have been on the mar­ket for about five years, but the al­lo­gene­ic ap­proach has lin­gered be­hind due to var­i­ous im­mune sys­tem com­plex­i­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.